Site map
|
Privacy policy
|
Contact us
Merck / Schering-Plough Press Releases
Information From Merck and Schering-Plough
FDA Communications
Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study - 03/30/08
Results from ENHANCE Study - 03/30/08
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial – 01/25/08
ENHANCE Chronology – 01/25/08
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial – 01/14/08
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial – 11/19/07
Prescribing Information and Patient Product Information for VYTORIN
®
(ezetimibe/simvastatin)
Prescribing Information and Patient Product Information for ZETIA
®
(ezetimibe)
Message to Patients about Recent News on VYTORIN
®
(ezetimibe/simvastatin) and ZETIA
®
(ezetimibe) – 01/19/08
Prescribing Information and Patient Product Information for VYTORIN
®
(ezetimibe/simvastatin)
Prescribing Information and Patient Product Information for ZETIA
®
(ezetimibe)
Update of Safety Review: Follow-up to the January 25, 2008 Early Communication about an Ongoing Data
Review for Ezetimibe/Simvastatin (marketed as VYTORIN), Ezetimibe (marketed as ZETIA), and Simvastatin
(marketed as Zocor)
FDA Issues Early Communciation about an Ongoing Review of VYTORIN
Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as VYTORIN),
Ezetimibe (marketed as ZETIA), and
Simvastatin (marketed as Zocor)
Transcript of FDA Press Conference on Early Communication about an Ongoing Review of VYTORIN
Prescribing Information and Patient Product Information for VYTORIN
®
(ezetimibe/simvastatin)
Prescribing Information and Patient Product Information for ZETIA
®
(ezetimibe)
To view PDF documents, you must have Adobe Reader installed on your computer.